Linked Data API

Show Search Form

Search Results

1108693
star this property registered interest false more like this
star this property date less than 2019-04-01more like thismore than 2019-04-01
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
unstar this property hansard heading Cannabis: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on the prescription of medicinal cannabis oil for patients with (a) cerebral palsy and (b) arthritis. more like this
unstar this property tabling member constituency Banff and Buchan more like this
star this property tabling member printed
David Duguid more like this
star this property uin 239283 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-04-09more like thismore than 2019-04-09
star this property answer text <p>The Department has not discussed with the National Institute for Health and Care Excellence (NICE) the prescription of medicinal cannabis oil for patients with cerebral palsy and arthritis.</p><p> </p><p>NICE is the independent expert body that develops authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources. NICE is developing guidance on the prescribing of cannabis-based medicinal products by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for delivering such guidance.</p><p> </p><p>Following a public consultation on the draft scope, the guidance will focus on the use of cannabis-based products in the treatment of chronic pain, intractable nausea and vomiting, spasticity and severe treatment-resistant epilepsy, conditions where the evidence is currently most advanced. A consultation on the draft guidance is expected in the summer.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
remove filter
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4606
unstar this property label Biography information for David Duguid more like this